Moors & Cabot’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $975K | Buy |
20,331
+1,349
| +7% | +$58K | 0.04% | 392 |
|
|
2026
Q1 | $698K | Buy |
18,982
+888
| +5% | +$42.1K | 0.03% | 461 |
|
|
2025
Q4 | $921K | Sell |
18,094
-2,357
| -12% | -$121K | 0.04% | 373 |
|
|
2025
Q3 | $1.13M | Buy |
20,451
+6,328
| +45% | +$370K | 0.05% | 332 |
|
|
2025
Q2 | $975K | Buy |
14,123
+7,248
| +105% | +$493K | 0.05% | 344 |
|
|
2025
Q1 | $477K | Buy |
6,875
+663
| +11% | +$54.8K | 0.02% | 497 |
|
|
2024
Q4 | $534K | Sell |
6,212
-780
| -11% | -$84.3K | 0.03% | 485 |
|
|
2024
Q3 | $833K | Buy |
6,992
+10
| +0.1% | +$1.33K | 0.04% | 381 |
|
|
2024
Q2 | $997K | Sell |
6,982
-65
| -0.9% | -$8.61K | 0.05% | 309 |
|
|
2024
Q1 | $905K | Buy |
7,047
+1,600
| +29% | +$190K | 0.05% | 329 |
|
|
2023
Q4 | $563K | Sell |
5,447
-503
| -8% | -$49.7K | 0.04% | 429 |
|
|
2023
Q3 | $541K | Buy |
5,950
+510
| +9% | +$44.9K | 0.04% | 409 |
|
|
2023
Q2 | $440K | Buy |
5,440
+746
| +16% | +$60.9K | 0.03% | 483 |
|
|
2023
Q1 | $374K | Sell |
4,694
-100
| -2% | -$7.09K | 0.03% | 529 |
|
|
2022
Q4 | $324K | Sell |
4,794
-406
| -8% | -$23.8K | 0.02% | 559 |
|
|
2022
Q3 | $259K | Sell |
5,200
-296
| -5% | -$15.9K | 0.02% | 615 |
|
|
2022
Q2 | $306K | Buy |
5,496
+284
| +5% | +$15.8K | 0.02% | 554 |
|
|
2022
Q1 | $289K | Sell |
5,212
-16
| -0.3% | -$821 | 0.02% | 640 |
|
|
2021
Q4 | $293K | Sell |
5,228
-12,228
| -70% | -$662K | 0.02% | 645 |
|
|
2021
Q3 | $836K | Buy |
17,456
+12,228
| +234% | +$591K | 0.05% | 313 |
|
|
2021
Q2 | $219K | Buy |
+5,228
| New | +$203K | 0.02% | 703 |
|
|
2021
Q1 | – | Sell |
-7,228
| Closed | -$253K | – | 823 |
|
|
2020
Q4 | $253K | Hold |
7,228
| – | – | 0.02% | 572 |
|
|
2020
Q3 | $251K | Sell |
7,228
-110
| -1% | -$3.67K | 0.02% | 525 |
|
|
2020
Q2 | $239K | Buy |
+7,338
| New | +$234K | 0.03% | 519 |
|
|
2018
Q1 | – | Sell |
-8,050
| Closed | -$216K | – | 600 |
|
|
2017
Q4 | $216K | Buy |
+8,050
| New | +$205K | 0.03% | 501 |
|
|
2016
Q3 | – | Sell |
-29,864
| Closed | -$802K | – | 553 |
|
|
2016
Q2 | $802K | Sell |
29,864
-470
| -2% | -$12.9K | 0.14% | 179 |
|
|
2016
Q1 | $822K | Sell |
30,334
-12,866
| -30% | -$345K | 0.15% | 175 |
|
|
2015
Q4 | $1.25M | Sell |
43,200
-4,830
| -10% | -$134K | 0.23% | 119 |
|
|
2015
Q3 | $1.3M | Buy |
48,030
+4,700
| +11% | +$133K | 0.24% | 111 |
|
|
2015
Q2 | $1.18M | Buy |
43,330
+100
| +0.2% | +$2.81K | 0.19% | 130 |
|
|
2015
Q1 | $1.16M | Sell |
43,230
-1,550
| -3% | -$35.7K | 0.19% | 129 |
|
|
2014
Q4 | $939K | Buy |
44,780
+150
| +0.3% | +$3.35K | 0.16% | 150 |
|
|
2014
Q3 | $1.07M | Sell |
44,630
-2,630
| -6% | -$60.5K | 0.18% | 130 |
|
|
2014
Q2 | $1.09M | Buy |
+47,260
| New | +$1.04M | 0.18% | 129 |
|
Other funds holding NVO
F
Moors & Cabot's NVO Position: Q2 2026 in Review
Moors & Cabot increased its Novo Nordisk (NVO) stake by 7.1% in Q2 2026, buying an estimated $58K and bringing the position to 20,331 shares worth $975K. The position accounts for 0.04% of the portfolio, ranked #392.
Moors & Cabot first reported a position in NVO in Q2 2014 and has held it in 34 quarters since. The position peaked at $1.3M in Q3 2015. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.
- Moors & Cabot held 20,331 shares of Novo Nordisk worth $975K as of Q2 2026.
- Moors & Cabot bought 1,349 Novo Nordisk shares in Q2 2026, an estimated $58K.
- Novo Nordisk made up 0.04% of Moors & Cabot's portfolio in Q2 2026, its #392 holding.
- Moors & Cabot first reported a position in Novo Nordisk in Q2 2014 and has held it in 34 quarters since.
- Moors & Cabot's Novo Nordisk position peaked at $1.3M in Q3 2015.
- 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.
Based on Moors & Cabot's 13F filing for Q2 2026, filed 10 Aug 2026.